- LP-184 is the first of Lantern’s drug candidates developed by
leveraging Lantern’s AI platform, RADR®
- US FDA previously granted LP-184 Rare Pediatric Disease
Designation and Orphan Drug Designation (ODD) for the treatment of
pediatric patients with ATRT
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence
(AI) company developing targeted and transformative cancer
therapies using its proprietary RADR® AI and machine learning (ML)
platform with multiple clinical-stage drug programs, received a
notice of allowance from the United States Patent and Trademark
Office (USPTO) covering a method of treatment for Atypical Teratoid
Rhabdoid Tumor (ATRT) using LP-184, an aggressive and rapidly
growing form of cancer of the central nervous system (CNS).
“This patent allowance further fortifies Lantern Pharma's
intellectual property portfolio, providing us with an additional
layer of protection for our potential blockbuster LP-184 program,
which is being developed for multiple targeted oncology
indications, including ATRT in pediatric patients,” said Panna
Sharma, CEO of Lantern Pharma. “Historically, pediatric ATRT has
been treated with a combination of surgery, radiation, and
chemotherapy, but unfortunately, these approaches have often
resulted in unfavorable long-term outcomes for the children
affected.”
Drs. Kosj and Jaymi Yamoah, Co-founders of Hope4ATRT, a research
entity dedicated to directing resources and research to families in
the fight against ATRT, commented, “As parents of a child who did
not survive ATRT, we are compelled to advocate for more effective
and less toxic treatment options for children still in this battle,
and we are always thrilled to see progress in ATRT research. The
work by Lantern scientists to rapidly develop new therapies with
potential to treat ATRT brings us hope for the future.”
Sharma continued, “The urgent need for new treatment options for
pediatric brain cancers cannot be overstated. Our in-silico and
in-vivo observations indicate that LP-184 has the potential to
become an essential part of the treatment options for these
patients, and this patent allowance provides a further assurance of
protection for our advances in the treatment of this devastating
disease.”
LP-184 is the first of Lantern’s drug candidates developed by
leveraging Lantern’s AI and ML platform, RADR®, to advance to a
first-in-human Phase 1 basket trial. Lantern has rapidly advanced
the clinical development of LP-184, activated the initial clinical
trial sites, and has begun screening patients. Indications for the
LP-184 trial are anticipated to include relapsed/refractory
advanced pancreatic cancer, glioblastoma (GBM), brain metastases
(brain mets), and multiple other recurring, advanced solid tumors
with DNA damage response deficiencies.
The dosage and safety data obtained in the Phase 1 trial will be
used to advance the CNS indications, including ATRT, for a future
Phase 2 trial to be sponsored by Lantern’s wholly-owned subsidiary,
Starlight Therapeutics Inc. Globally, the aggregate annual market
potential of LP-184’s target indications is estimated to be
approximately $10+ billion, consisting of $5+ billion for CNS
cancers and $6+ billion for other solid tumors.
The U.S. Food and Drug Administration (FDA) has previously
granted LP-184 Rare Pediatric Disease Designation and Orphan Drug
Designation (ODD) for the treatment of pediatric patients with
ATRT. The FDA has also previously granted LP-184 ODD for the
treatment of pancreatic cancer and for the treatment of malignant
glioma, including GBM.
A notice of allowance is issued after the USPTO determines that
the prosecution on the merits of a patent has been completed and
grants the patent upon payment of the patent issuance fee.
Additional corresponding patent applications are pending in Europe,
Japan, Canada, and Australia.
About ATRT
ATRT is an aggressive and rare form of cancer of the central
nervous system that predominantly affects children under the age of
three. The National Cancer Institute (NCI) classifies ATRT as Grade
IV tumors, meaning they are malignant (cancerous), aggressive, and
fast-growing. The root genetic cause of ATRTs is attributed to
bi-allelic mutations that inactivate either SMARCB1 (also known as
INI1) or SMARCA4. Approximately 90 percent of pediatric ATRTs can
be attributed to alterations in the SMARCB1 gene. SMARCB1 was
included among several genes whose expression negatively correlated
with LP-184 sensitivity in tumors. This in silico correlation was
confirmed by in vitro and in vivo assessments of LP-184 in ATRT,
with the highest potency of LP-184 in vivo having been seen in ATRT
xenografts.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the
cost, pace, and timeline of oncology drug discovery and
development. Our proprietary AI and machine learning (ML) RADR®
platform leverages over 34 billion oncology-focused data points and
a library of 200+ advanced ML algorithms to help solve
billion-dollar, real-world problems in oncology drug development.
By harnessing the power of AI and with input from world-class
scientific advisors and collaborators, we have accelerated the
development of our growing pipeline of therapies including eleven
cancer indications and an antibody-drug conjugate (ADC) program. On
average, our newly developed drug programs have been advanced from
initial AI insights to first-in-human clinical trials in 2-3 years
and at approximately $1.0-2.0 million per program.
Our lead development programs include two Phase 2 clinical
programs and multiple upcoming Phase 1 clinical trials anticipated
for 2023. We have also established a wholly-owned subsidiary,
Starlight Therapeutics Inc., to focus exclusively on the clinical
execution of our promising therapies for CNS and brain cancers,
many of which have no effective treatment options. Our AI-driven
pipeline of innovative product candidates is estimated to have a
combined annual market potential of over $15 billion USD and have
the potential to provide life-changing therapies to hundreds of
thousands of cancer patients across the world.
Please find more information at:
Website: www.lanternpharma.com LinkedIn:
https://www.linkedin.com/company/lanternpharma/ X/Twitter:
@lanternpharma Newsletter – The Spark: Sign-up here
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and biomarker
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the risk that our research
and the research of our collaborators may not be successful, (ii)
the risk that none of our product candidates has received FDA
marketing approval, and we may not be able to successfully
initiate, conduct, or conclude clinical testing for or obtain
marketing approval for our product candidates, (iii) the risk that
no drug product based on our proprietary RADR® AI platform has
received FDA marketing approval or otherwise been incorporated into
a commercial product, and (iv) those other factors set forth in the
Risk Factors section in our Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the Securities and Exchange
Commission on March 20, 2023. You may access our Annual Report on
Form 10-K for the year ended December 31, 2022 under the investor
SEC filings tab of our website at www.lanternpharma.com or on the
SEC's website at www.sec.gov. Given these risks and uncertainties,
we can give no assurances that our forward-looking statements will
prove to be accurate, or that any other results or events projected
or contemplated by our forward-looking statements will in fact
occur, and we caution investors not to place undue reliance on
these statements. All forward-looking statements in this press
release represent our judgment as of the date hereof, and, except
as otherwise required by law, we disclaim any obligation to update
any forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230814886764/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Lantern Pharma (NASDAQ:LTRN)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
